Glucose-dependent insulinotropic polypeptide (GIP) is glucagonotropic and glucagon-like peptide 1 (GLP-1) is glucagonostatic. We studied the effects of GIP and GLP-1 on glucagon responses to insulin-induced hypoglycemia in patients with type 1 diabetes mellitus (T1DM).
Introduction
In recent years, it has become evident that glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) have glucose-dependent effects on glucagon secretion (1) . While GLP-1 lowers glucagon levels during fasting and elevated blood glucose (1-3), GIP raises glucagon levels during fasting and hypoglycemic conditions (4) (5) (6) . In most patients with type 1 diabetes (T1DM), the glucagon counter-regulatory response to insulin-induced hypoglycemia is deficient (7, 8) , and it is unknown to what extent the incretin hormones might affect this response. We therefore studied the individual effects of GIP and GLP-1 on the glucagon response to insulin-induced hypoglycemia in patients with T1DM without endogenous insulin secretion.
Research design and methods

Study design
This was a double-blinded, randomized, cross-over study comparing the effects of GIP, GLP-1 and placebo (saline) on the glucagon response to insulin-induced hypoglycemia in patients with T1DM.
The study was conducted at Gentofte Hospital, University of Copenhagen. The study was approved by 
Participants
We included 10 male patients (age: 26±1 years (mean±SEM); BMI: 24±0.5 kg/m 2 ; glycated hemoglobin A1c (HbA1c): 7.3±0.2%) with T1DM (positive islet cell and/or glutamic acid decarboxylase-65 antibodies), treated with multiple doses of insulin (N=9) or insulin pump (N=1), without late diabetic complications, hypoglycemia unawareness and residual beta cell function (i.e. Cpeptide negative following a 5 g-arginine stimulation test (9)).
Experimental procedures
Each patient underwent three separate study days in randomized order with intervals of at least one week. Subjects were instructed to maintain a regular diet and avoid alcohol and physical activity for three days prior to each study day. Subjects were asked to wear a Guardian ® REAL-time continuous glucose monitor (Medtronic A/S, Copenhagen, Denmark) for 2-4 days before each study day to monitor glycemic variability and facilitate therapeutic decisions in relation to food intake and insulin delivery. If patients had fasting plasma glucose levels between 5 and 9 mmol/l at the morning of the study day, two cannulas were inserted bilaterally into the cubital veins for infusions and blood sampling, respectively. Two hours before study start (i. ), or placebo (saline) were initiated and continued for the remainder of the study that day. Plasma glucose was measured bedside every 5
minute. An adjustable continuous infusion of 20% dextrose (w/v) was administered by a physician (SC) unaware of randomization allocation to keep plasma glucose above 2 mmol/l in the time interval 0-75 min and above 3.5 mmol/l in the interval 75-120 min. Hypoglycemic symptoms and cognitive function were assessed at baseline (time -60 min) and during hypoglycemia (time 65 min) using validated rating scales (10). as previously described (5, 11) . We used the assay for total GLP-1 to allow for comparison between GLP-1 concentrations in healthy volunteers (12) and during subcutaneous treatment with GLP-1 (13) .
Analytical procedures
Blood enrichment of D 2 -glucose and D 5 -glycerol was determined using gas chromatography mass spectrometry as previously described (14) . Plasma insulin, C-peptide, cortisol, noradrenaline, and growth hormone were measured with commercial immunoassays.
Calculations and statistical analyses
To detect a real difference in glucagon responses between days of at least 2.5 pmol/l with a two-sided 5% significance level, a power of 80%, and a within-patient standard deviation of plasma glucagon measurements of 1.7 pmol/l (estimated from a previous study (5)), a sample size of 10 patients was found to be necessary. Area under the curve (AUC) and incremental AUC (iAUC) i.e. baseline levelsubtracted AUC-values were calculated using the trapezoidal rule. Glucose rate of appearance (R a ) and glucose rate of disappearance (R d ) were calculated from the changes in glucose enrichment using a one-compartment, fixed-volume, non-steady-state model modified for use with stable isotopes and a pool fraction of 70 ml×kg -1 (15) . To test for differences in concentration time courses we used twoway repeated measures ANOVA followed by Holm-Šídák corrected post-tests. For comparisons of AUC values we used Friedman test followed by paired comparisons using Wilcoxon test. Statistics and graphical presentations were performed in Graphpad Prism version 6.01 (GraphPad Software, La Jolla, CA, USA). A two-sided P value <0.05 was used to indicate statistically significant differences.
Results are reported as mean±standard error of the mean (SEM) unless otherwise stated.
Results
Plasma glucose
Mean plasma glucose concentrations during each of the three experimental days are displayed in Figure 1a . Baseline plasma glucose concentrations (time -90 to 0 min) did not differ significantly 
GIP and GLP-1
Plasma concentrations over time of GIP and GLP-1 are shown in Figure 1 . The respective plasma concentrations peaked at 134±4 pmol/l during GIP infusion (Fig. 1b) and 219±19 pmol/l during GLP-1 infusion (Fig. 1c) .
Insulin and C-peptide
Serum insulin concentrations over time are presented in Figure 1d . Overall basal concentrations of serum insulin were similar on study days (P=0.58). After start of insulin infusion, levels of serum insulin increased significantly to overall mean peak levels of 810±129 pmol/l, with no difference in mean values between study days (P=0.52). Mean C-peptide concentrations were below the detection limit at all time points (data not shown). there was a higher glucagon response on the GIP days (P<0.02 vs. saline).
Glucagon
Glucose kinetics
The time courses of glucose R a and glucose R d were similar on study days ( Fig. 2a and 2b) . GIP infusion increased endogenous R a (significant at 75 min), whereas GLP-1 reduced endogenous R a compared to saline (time 90-120 min) (Fig 2c) . The glucose infusion rates also differed between days, with lower infusion rates on the days of GIP infusion at time 75 min (Fig. 2d) .
Free fatty acids, glycerol and glycerol kinetics
The levels of Free fatty acids (FFA) were equally suppressed during the first hour of the study, but during the 'recovery phase' they increased more on the days of GIP infusion as compared to saline (Fig. 3a) and FFA iAUC was higher on the GIP days (P<0.04). Plasma glycerol concentrations and glycerol R a and R d did not differ between study days ( Fig. 3c and 3d ).
Hypoglycemia symptom score and cognitive function
There were no differences in hypoglycemia symptom scores or cognitive function scores between the study days ( Fig. 4a and 4b ).
Plasma cortisol, noradrenalin and growth hormone responses
The plasma cortisol, noradrenalin and growth hormone concentrations did not differ significantly between study days (data not shown).
Discussion
We report that in patients with T1DM without residual beta cell function, GIP augments glucagon responses to experimental hypoglycemia and reduces the need for exogenous glucose administration (to prevent severe hypoglycemia) accompanied by a higher rate of endogenous glucose production (significantly higher at the time around maximal hypoglycemia, 75 minutes after study start) compared to placebo. We also report that GLP-1 infusions slightly suppress plasma glucagon during induction of hypoglycemia, with no additional need for exogenous glucose administration.
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GIP and GLP-1 during hypoglycemia in T1DM 8/23 The mechanism underlying these findings could be the direct action of the incretin hormones on the pancreatic alpha cells as demonstrated in perfused rat pancreata (16) . During perfusion with low levels of glucose (1.5 mmol/l), GIP had stimulatory and GLP-1 had inhibitory effects on glucagon secretion (16) . The glucagonotropic effect of GIP is presumed to be mediated by activation of GIP receptors present on pancreatic alpha cells (17, 18) . The glucagon inhibitory effects of GLP-1 have been attributed to paracrine inhibitory signaling (somatostatin) from neighboring delta cells (16) , or -more controversially -direct effects via GLP-1 receptors present on alpha cells (1,19).
We were not able to detect any differences between interventions in cognition, hypoglycemia symptoms, or other counter regulatory hormones. This is not surprising, as the glucose levels were similar on the three experimental days. Notably, the fact that glucose levels were kept above 2 mmol/l could explain the limited symptoms and hormonal responses to hypoglycemia. We demonstrated a minor GIP-dependent increase in free fatty acids and a non-significant increase in glycerol during the 'recovery phase' from hypoglycemia. This was unexpected, as a preponderance of evidence including human in vivo data support a role for GIP combined with insulin in stimulating postprandial lipogenesis (20, 21) . The observed paradoxical 'lipolytic effect' could therefore have depended on the low plasma glucose levels in combination with fairly low insulin levels and stimulated glucagon levels during the recovery phase after hypoglycemia.
A few considerations are worth mentioning. Firstly, we used doses of GIP and GLP-1 resulting in supraphysiological plasma levels. The plasma intact GIP levels of ~125 pmol/l were in the range that can be reached postprandially during DPP-4 inhibition (22) . The total GLP-1 levels of ~200 pmol/l were similar or slightly lower than what can be used therapeutically in patients with type 2 diabetes 
Figure 2. Glucose kinetics
The rate of glucose appearance (R a) (a), rate of glucose disappearance (R d ) (b), rate of endogenous glucose production (c), and glucose infusion rate in 15 minute intervals (d) during insulin-induced hypoglycemia with iv infusion of GIP (red diamonds), GLP-1 (blue hexagons) or saline (white squares). Data are means±SEM. Statistical analyses were done with repeated-measures ANOVA and denote differences over time (A), differences between the groups (B), and differences owing to interaction between group and time (AB). Post-tests at individual time points were by Holm-Sidak's multiple comparisons tests. Significant differences are indicated by asterisks: *P<0.05, **P=0.001 to 0.01, ***P=0.0001 to 0.001, ****P<0.0001. 
Supplementary material Figure 1. Plasma cortisol, noradrenalin and growth hormone
Concentrations of plasma cortisol (a) and growth hormone (b) and noradrenalin (c) during insulininduced hypoglycemia with iv infusion of GIP (red diamonds), GLP-1 (blue hexagons) or saline (white squares). Data are means±SEM. Statistical analyses were done with repeated measures ANOVA and denote differences over time (A), differences between the groups (B), and differences owing to interaction between group and time (AB)
